IRCT20210218050404N2CompletedPhase 2
Clinical evaluation of ZAX.1400.C01 in patients with coronavirus in Valiasr Hospital, Fasa, 2021
Fasa University of Medical Sciences0 sites60 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 60
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 65 years (—)
- Sex
- All
Inclusion Criteria
- •Definitive diagnosis of COVID-19 disease by laboratory test from the patient's lung sputum
- •Age from 18 to 65 years
- •Patient hemoglobin saturation (SPO2) between 85% and 93%
- •Detection of lung involvement percentage by CT scan
- •20-30 breaths per minute
- •informed consent by participate in the study
Exclusion Criteria
- •liver and kidney diseases
- •Pregnancy and lactation
- •anticoagulants administration (aspirin, Plavix, warfarin)
- •hypertension
- •History of allergies to plant products
- •Disagreement of the physician in charge of the patient before randomization
- •Inability of the patient to take oral medication
Investigators
Similar Trials
Not yet recruiting
Phase 3
Evaluation of therapeutic effects of ZAX.1400.C05 on patients with coronavirusCOVID-19 viral disease.Coronavirus infection, unspecifiedB34.2IRCT20210218050404N4Fasa University of Medical Sciences300
Not yet recruiting
Phase 1
BICICL: BTK and Immune Checkpoint Inhibitor in Central Nervous System (CNS) LymphomaCentral Nervous System LymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphomaACTRN12622000547741Monash University30
Completed
Phase 3
Clinical Study on the Efficacy and Safety of Z101101 in Total Hip ArthroplastyPatients who have been judged to require THAJPRN-UMIN000004797Zimmer K.K.69
Active, not recruiting
Not Applicable
Safety and Efficacy of XM 02 in patients with Non-Hodgkin-Lymphoma receiving chemotherapy.EUCTR2004-001449-13-LTBioGeneriX AG90
Active, not recruiting
Not Applicable
Safety and Efficacy of XM 02 in patients with Non-Hodgkin-Lymphoma receiving chemotherapy.Patients with Non-Hodgkin-Lymphoma receiving chemotherapy and developing Neutropenia due to chemotherapy.EUCTR2004-001449-13-HUBioGeneriX AG90